Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Reducing off-Target hERG Activity of First-Generation DCN1-UBE2M Interaction Inhibitors: Design, Synthesis, and Structure-Activity Relationships.

Created on 12 Nov 2026

Authors

Tara Man Kadayat, Gaurav Shoeran, Daniel C Scott, Kristin L Begley, Jared T Hammill, Jong Yeon Hwang, Tucker J Moseley, Ho Shin Kim, Agripina G Deaciuc, Moeko T King, Bhuvanesh Singh, Brenda A Schulman, R Kiplin Guy

Published in

Journal of medicinal chemistry. Volume 69. Issue 21. Pages 26231-26247. Nov 12, 2026.

Abstract

We previously reported a potent and orally available inhibitor (2, NAcM-OPT) of the DCN1-UBE2M protein interaction that targets the neddylation pathway to potentially regulate oncogenic transformation for the treatment of cancer. In vivo profiling of compound 2 revealed that, while it was potent, orally bioavailable, and inhibited growth of tumor xenografts in immunodeficient mice, it possessed significant off-target affinity for the human ether-a-go-go-related gene protein (hERG Ki = 750 nM), thereby significantly limiting its potential for development. Herein, we disclose the rational and systematic modification of compound 2 to reduce the affinity for hERG while maintaining its affinity for and activity against DCN1. These studies led to the discovery of compound 110, which exhibited equivalent biochemical and cellular potency to 2, improved physicochemical properties, and increased selectivity relative to hERG.

PMID:
43018587
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement